Top executives for genome-editing companies on Monday pushed back against a new unpublished paper that raised concerns about preexisting immune responses to CRISPR-based therapies, insisting the issues outlined in the study were either already being addressed or were not relevant to the medicines being developed.

The paper, which was posted Friday on the preprint site bioRxiv, sent shares of Intellia Therapeutics and Editas Medicine down sharply Monday morning. Shares of CRISPR Therapeutics also declined.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy